



## **Biosign Supplies UFIT<sup>®</sup> Monitors to Landmark Chronic Pain Study**

**TORONTO, ONTARIO, Thursday, July 30, 2009** – Biosign Technologies Inc. (CNSX: **BIO**) today announced the commercial launch of its UFIT<sup>®</sup> system in the medical research market. Under the terms of a purchase order from Algogene Pain Genetics, Biosign will supply UFIT<sup>®</sup> devices and online test, measurement, and analysis services to a study on chronic pain.

The study is a collaboration between The University of Toronto Centre for the Study of Pain, The Centre for International Health, and Algogene Pain Genetics. The collaboration is primarily aimed at identifying pain mechanisms and genetic targets for developing better pain medication.

Biosign's technology will be used to assess blood pressure, blood glucose, autonomic nervous system features, and other parameters in 4,500 amputees over one year.

“In spite of a rigorous search, we were unable to find another non-invasive measurement system that provides the kind of power and versatility required for studying the interplay between morbidities such as hypertension and diabetes associated with untreatable persistent pain”, said Dr. Ze'ev Seltzer, the study's lead investigator, a professor of genetics at the Faculties of Dentistry and Medicine at the University of Toronto, who holds a Canada Research Chair in Pain Genetics.

Contact:

Radu Leca, President & CEO

Biosign Technologies Inc.

Phone: (416) 218-9800 ext. 234

Email: [ceo@biosign.com](mailto:ceo@biosign.com)

## ***About Biosign Technologies Inc.***

Biosign provides technologies, products and initiatives to address critical problems in global health care. The focus is on monitoring health status, outcomes, and risk toward maximizing clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical care to optimize healthcare quality, access, and cost. The core technology expands virtual instrumentation with universal measurement and rapid knowledge formation to support service oriented enterprising across global markets. Trademarked UFIT, the web-based technology powers several business lines in self-care, wellness, remote patient monitoring, and chronic disease evaluation and management. Key applications include intelligent systems for noninvasive monitoring of common health risks such as high blood pressure, high blood glucose, and adverse responses to medication. For more information on Biosign please visit <http://www.biosign.com>

**The CNSX has neither approved nor disapproved the contents of this press release.**

*THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR  
FOR DISSEMINATION IN THE UNITED STATES*

Certain information regarding the Company including management's assessment of future plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve risks associated with medical technology companies, research and development, volatility of prices, currency fluctuations, imprecision of estimates, business environment risks, access to labor and services, competition from other companies and ability to access sufficient capital. As a consequence, actual results may differ materially from those anticipated in any forward-looking statements. The Canadian National Stock Exchange (CNSX) does not accept responsibility for the adequacy or accuracy of this release.